Exact Sciences Corp. (NASDAQ:EXAS) – Research analysts at Jefferies Group issued their FY2018 EPS estimates for shares of Exact Sciences Corp. in a research report issued on Wednesday. Jefferies Group analyst B. Couillard expects that the brokerage will post earnings per share of ($0.86) for the year. Jefferies Group has a “Buy” rating and a $20.00 price target on the stock.
A number of other research analysts also recently weighed in on the company. Craig Hallum raised their price objective on Exact Sciences Corp. from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday. Benchmark Co. dropped their price target on Exact Sciences Corp. from $14.00 to $9.00 and set a “hold” rating on the stock in a research report on Wednesday. Mizuho lifted their price target on Exact Sciences Corp. from $10.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday. Canaccord Genuity reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a research report on Tuesday. Finally, William Blair reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Exact Sciences Corp. in a research report on Friday, July 15th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.20.
Shares of Exact Sciences Corp. (NASDAQ:EXAS) traded up 2.97% during midday trading on Thursday, reaching $17.32. The company’s stock had a trading volume of 19,214,401 shares. The stock has a 50 day moving average price of $11.52 and a 200-day moving average price of $7.72. The company’s market capitalization is $1.70 billion. Exact Sciences Corp. has a 52-week low of $4.67 and a 52-week high of $24.74.
A hedge fund recently bought a new stake in Exact Sciences Corp. stock. Eagle Asset Management acquired a new stake in shares of Exact Sciences Corp. (NASDAQ:EXAS) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,216,894 shares of the company’s stock, valued at approximately $39,880,000. Eagle Asset Management owned 2.30% of Exact Sciences Corp. at the end of the most recent quarter.
In other Exact Sciences Corp. news, insider Graham Peter Lidgard sold 7,383 shares of Exact Sciences Corp. stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.82, for a total value of $109,416.06. Following the completion of the transaction, the insider now owns 227,592 shares in the company, valued at approximately $3,372,913.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Maneesh Arora sold 7,359 shares of Exact Sciences Corp. stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $14.82, for a total value of $109,060.38. Following the completion of the transaction, the chief operating officer now owns 538,736 shares of the company’s stock, valued at approximately $7,984,067.52. The disclosure for this sale can be found here.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.
